-+ 0.00%
-+ 0.00%
-+ 0.00%

Roth Capital Maintains Buy on Cingulate, Lowers Price Target to $14

Benzinga·03/23/2026 17:26:29
Listen to the news
Roth Capital analyst Boobalan Pachaiyappan maintains Cingulate (NASDAQ:CING) with a Buy and lowers the price target from $16 to $14.